– Study met primary endpoint (p-value = 0.012) -First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG -Results support planned Supplemental Biologics License Application… Read More
Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary hypertension (PH) patients while reducing the risk… Read More
30,000 ft2 center will help biopharma shorten development timelines, reduce risk, and scale with confidence Supports multiple modalities including mAbs, pDNA/mRNA, recombinant proteins, and viral vectors Cytiva, a Danaher company and… Read More
Ontario’s FAST program aims to speed up access to breakthrough cancer drugs for patients by almost a full year sooner.[1] Itovebi offers a targeted treatment for advanced HR-positive, HER2-negative breast… Read More
Corcym, a global medical device company focused on advanced cardiac surgery solutions, announced that Health Canada has approved the Miami Instruments™ portfolio, a suite of minimally invasive surgical instruments designed… Read More
